The expression of Program Death ligand 1 (PD-L1) by CD34+ CMML cells was reported higher than in AML and MDS and increased during hypomethylating agent treatment associated with poorer survival, suggesting an immune escape mechanism [106]. The gene discussed is CD34; the disease is acute myeloid leukemia.